Kratom and Opioid Addiction: What You Need to Know

Key Takeaways

• Kratom (Mitragyna speciosa) acts on opioid receptors and is used by some individuals to self-manage opioid withdrawal symptoms, but it is not FDA-approved for any medical use.
• Kratom carries its own addiction and dependence potential, and withdrawal from kratom is well-documented and clinically significant.
• The FDA has issued warnings against kratom use, citing safety concerns including contamination, inconsistent potency, and reported deaths.
• Kratom is legal in New Jersey but unregulated, meaning product quality, purity, and dosing are not standardized.
• FDA-approved medications — buprenorphine (Suboxone/Sublocade), methadone (Dolophine/Methadose), and naltrexone (Vivitrol) — have robust evidence bases that kratom lacks.
• Individuals using kratom to manage opioid withdrawal should be aware of the risks and informed about evidence-based alternatives.

Kratom has emerged as a controversial topic in the addiction treatment landscape. Widely available in gas stations, smoke shops, and online retailers, kratom is marketed by proponents as a natural remedy for opioid withdrawal, chronic pain, and depression. The reality is more complicated. While kratom does interact with opioid receptors — which explains its ability to alleviate some withdrawal symptoms — its safety profile, addiction potential, and lack of regulatory oversight raise serious concerns that individuals and families should understand before using it.

This page examines the evidence on kratom in the context of opioid addiction, including what it does, what the research shows, and why clinicians generally recommend FDA-approved alternatives.

What Is Kratom and Why Do People Use It

How Kratom Interacts with Opioid Receptors

Kratom (Mitragyna speciosa) is a tropical tree native to Southeast Asia. Its leaves contain two primary active compounds:

• Mitragynine — the most abundant alkaloid, which acts as a partial agonist at mu-opioid receptors at higher doses and has stimulant properties at lower doses
• 7-hydroxymitragynine — present in smaller quantities but significantly more potent at opioid receptors than mitragynine

This dual pharmacology explains kratom’s dose-dependent effects:

• At low doses (1-5 grams of leaf material): Stimulant-like effects — increased energy, alertness, and sociability
• At higher doses (5-15 grams): Opioid-like effects — pain relief, sedation, euphoria, and suppression of opioid withdrawal symptoms

Because kratom activates opioid receptors, it can temporarily reduce the symptoms of opioid withdrawal. This pharmacological reality drives much of its appeal among individuals attempting to manage withdrawal without medical supervision.

Common Claims About Kratom for Withdrawal

Advocacy communities — many of which are active on platforms like Reddit — promote kratom for several purposes related to opioid addiction:

• Self-managed withdrawal: Using kratom to reduce withdrawal symptoms when transitioning off heroin, fentanyl, or prescription opioids
• Harm reduction: Substituting kratom for more dangerous opioids as a step toward cessation
• Relapse prevention: Using kratom to manage cravings during recovery
• Pain management: Replacing prescription opioids with kratom for chronic pain

These claims reflect genuine user experiences but lack the controlled clinical trial data that would establish kratom as a safe and effective treatment. The gap between individual testimonials and scientific evidence is substantial.

The Evidence on Kratom for Opioid Withdrawal

What Research Shows

The scientific literature on kratom for opioid withdrawal is limited but growing:

• Preclinical studies (animal models) suggest that mitragynine has analgesic and anti-withdrawal properties mediated through opioid receptors
• Survey data from kratom users consistently reports that many use it for self-treatment of pain, depression, and opioid withdrawal
• Case reports document both positive outcomes (individuals who used kratom to transition off opioids) and negative outcomes (individuals who developed kratom dependence, experienced toxic effects, or relapsed)
• No randomized controlled trials have been completed comparing kratom to FDA-approved MAT medications for opioid withdrawal management

The absence of controlled trial data is the critical gap. Without randomized studies, it is impossible to determine kratom’s true effectiveness, optimal dosing, safety profile in diverse populations, or how its outcomes compare to buprenorphine (Suboxone/Sublocade), methadone (Dolophine/Methadose), or naltrexone (Vivitrol).

NIDA has funded research into mitragynine-derived compounds as potential therapeutic agents, reflecting scientific interest in the underlying pharmacology even as the crude kratom product remains unapproved.

FDA and DEA Positions

Federal agencies have taken a cautious-to-negative stance on kratom:

FDA: Has issued multiple public health advisories warning against kratom use. The FDA’s concerns include:

• No FDA-approved kratom products exist for any medical indication
• The FDA has identified kratom as an opioid based on its receptor activity
• Reports of deaths associated with kratom use (often involving polysubstance use, but FDA considers them concerning)
• Contamination issues — kratom products have been recalled for Salmonella contamination
• Marketing of kratom with unapproved drug claims

DEA: Considered scheduling kratom as a controlled substance in 2016 but withdrew the proposal after public backlash. As of 2026, kratom remains unscheduled at the federal level, though the DEA continues to express concern about its safety.

The tension between user communities that view kratom as a harm reduction tool and federal agencies that view it as an unregulated opioid is unlikely to be resolved without rigorous clinical trial data.

Kratom Addiction and Dependence Risks

Can You Get Addicted to Kratom

Because kratom activates opioid receptors, regular use can produce physical dependence and, in some cases, a pattern of compulsive use consistent with substance use disorder. Clinical literature documents:

• Tolerance development: Regular kratom users report needing escalating doses to achieve the same effects, consistent with mu-opioid receptor tolerance
• Physical dependence: Stopping kratom after regular use produces a withdrawal syndrome with opioid-like features
• Compulsive use patterns: Some individuals report inability to control their kratom use, continued use despite negative consequences, and preoccupation with obtaining kratom — features that meet DSM-5 criteria for substance use disorder
• Dose escalation: Users who begin with low stimulant doses may progress to high sedative doses as tolerance develops

The risk of kratom addiction is not universal. Many individuals use kratom without developing problematic patterns. However, the risk is genuine, particularly for individuals with a history of opioid use disorder — a population that, paradoxically, is most likely to use kratom for withdrawal management.

Kratom Withdrawal Symptoms

Kratom withdrawal is documented in clinical literature and reported by users. Symptoms overlap significantly with opioid withdrawal:

• Anxiety and irritability
• Muscle aches and pain
• Insomnia
• Nausea and vomiting
• Sweating
• Tremors
• Diarrhea
• Drug cravings

Withdrawal severity correlates with the dose and duration of use. Individuals who use high doses of kratom for extended periods report withdrawal comparable to moderate opioid withdrawal. Symptoms typically begin within 12 to 24 hours of the last dose and peak within 2 to 4 days.

The clinical significance of kratom withdrawal is that individuals who turn to kratom to avoid opioid withdrawal may find themselves facing a new withdrawal syndrome — effectively trading one dependence for another without addressing the underlying opioid use disorder.

Kratom Legal Status and Safety Concerns

Legal Status in New Jersey

Kratom is legal to purchase, possess, and use in New Jersey. The state has not enacted specific kratom legislation, meaning it is available in:

• Smoke shops and vape stores
• Gas stations and convenience stores
• Online retailers that ship to NJ
• Some health food stores

Several other states have banned kratom or restricted its sale. The American Kratom Association has promoted the Kratom Consumer Protection Act (KCPA) in various states, which would regulate kratom products rather than ban them. New Jersey has not enacted KCPA legislation as of 2026.

Contamination and Quality Issues

The lack of FDA regulation means kratom products are not subject to the manufacturing standards required for pharmaceutical drugs or even dietary supplements. Documented quality concerns include:

• Salmonella contamination: The FDA linked a multi-state Salmonella outbreak to contaminated kratom products, resulting in recalls
• Heavy metal contamination: Testing has found elevated levels of lead and other heavy metals in some kratom products
• Inconsistent alkaloid content: The active ingredient concentration varies widely between products and even between batches from the same manufacturer
• Adulteration: Some kratom products have been found to contain synthetic opioids, prescription medications, or other undeclared substances
• No standardized dosing: Without quality controls, users cannot reliably dose kratom, increasing the risk of both underdosing (ineffective) and overdosing (potentially dangerous)

These quality issues compound the inherent pharmacological risks and make it impossible to assess kratom’s true safety profile from consumer-grade products.

Evidence-Based Alternatives to Kratom

MAT as the Gold Standard

For individuals seeking relief from opioid withdrawal and cravings, FDA-approved medications offer what kratom cannot: proven efficacy, standardized dosing, known safety profiles, and clinical oversight.

Buprenorphine (Suboxone/Sublocade):

• Partial opioid agonist with a similar mechanism to kratom’s active compounds, but with decades of clinical trial data
• Standardized pharmaceutical manufacturing ensures consistent potency
• Available in multiple formulations including monthly injection (Sublocade) that eliminates daily dosing
• Covered by NJ Medicaid and most commercial insurance plans
• Can be prescribed by any DEA-licensed physician since the X-waiver elimination in 2023

Methadone (Dolophine/Methadose):

• Full opioid agonist with the longest track record of any MAT medication
• Dispensed through licensed OTPs with clinical monitoring
• Effective for individuals with severe dependence who need full agonist support
• Covered by NJ Medicaid

Naltrexone (Vivitrol):

• Opioid antagonist that blocks opioid effects entirely
• Monthly injection formulation eliminates daily adherence concerns
• Appropriate for individuals who have completed detox and prefer an abstinence-based medication approach

Why Medical Supervision Matters

The central argument for FDA-approved MAT over kratom is not that kratom is pharmacologically implausible — it acts on the same receptors — but that medical supervision provides:

• Clinical assessment: Determining the appropriate level of care based on individual factors
• Dose optimization: Adjusting medication to effectively control withdrawal and cravings without excessive sedation
• Safety monitoring: Detecting and managing complications, drug interactions, and co-occurring conditions
• Contamination-free medication: Pharmaceutical-grade products with known purity and potency
• Treatment continuity: A plan that extends beyond withdrawal management into long-term recovery
• Insurance coverage: FDA-approved medications are covered by insurance; kratom is not

For individuals currently using kratom for opioid withdrawal management, transitioning to FDA-approved MAT under medical supervision is recommended. The NJ Substance Abuse Treatment Hotline (1-844-276-2777) can connect individuals with providers who can facilitate this transition.

---

This article is part of our complete guide to opioid addiction in New Jersey. For information on Suboxone as an evidence-based alternative, see Suboxone treatment: how it works. For more on withdrawal management, visit opioid withdrawal medications and treatment.

For information on medication-assisted treatment, see our guide to MAT. For Vivitrol-specific information, visit our Vivitrol glossary entry.